Compugen Adds Two Potential Therapeutic Proteins to its Research Pipeline.Business Editors/Health/Medical Writers BIO 2004 Annual Convention SAN FRANCISCO--(BUSINESS WIRE)--June 7, 2004 Speaking today at the BIO 2004 Annual International Convention, Martin Gerstel, Chairman of Compugen Ltd. (Nasdaq:CGEN CGEN Convective Sigmet Generation ), disclosed two novel potential therapeutic proteins which Compugen has recently added to its research pipeline: CGEN M-3, a soluble kinase receptor with potential applications in various types of cancer, and CGEN P-4, a peptide with potential applications in obesity and various eating disorders eating disorders, in psychology, disorders in eating patterns that comprise four categories: anorexia nervosa, bulimia, rumination disorder, and pica. Anorexia nervosa is characterized by self-starvation to avoid obesity. . The two proteins are naturally occurring molecules and each is a novel splice variant of a previously known protein. Through the use of Compugen's discovery engines, these proteins were initially predicted in-silico and are now being evaluated in Compugen's molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller laboratories. In his talk, Mr. Gerstel discussed Compugen's iterative it·er·a·tive adj. 1. Characterized by or involving repetition, recurrence, reiteration, or repetitiousness. 2. Grammar Frequentative. Noun 1. discovery process, combining predictive mathematical modeling with hypothesis-driven experimentation, and demonstrated how the power of this unique capability allows Compugen to obtain deeper understandings of important biological phenomena such as alternative splicing Alternative splicing is the RNA splicing variation mechanism in which the exons of the primary gene transcript, the pre-mRNA, are separated and reconnected so as to produce alternative ribonucleotide arrangements. and endogenous endogenous /en·dog·e·nous/ (en-doj´e-nus) produced within or caused by factors within the organism. en·dog·e·nous adj. 1. Originating or produced within an organism, tissue, or cell. antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). . These understandings, which are a key aspect of the Company's discovery engines, enable the identification of putative drug targets, biomarkers and therapeutic proteins and peptides, such as the two disclosed today, that would have been difficult to discover utilizing conventional experimental techniques Experimental research designs are used for the controlled testing of causal processes. The general procedure is one or more independent variables are manipulated to determine their effect on a dependent variable. . Furthermore, because of this unique predictive method, Compugen believes these discoveries have a higher probability for successful development into marketable drugs. During 2003, Compugen disclosed the first four potential therapeutic proteins in its internal pipeline, and stated that it would add six potential therapeutic proteins during 2004. CGEN M-3 and CGEN P-4 are the first two of these additional six to be disclosed. In the coming months, these new candidates will undergo further validation studies, either in Compugen's molecular biology laboratories or in collaboration with various research institutions. Compugen has filed patent applications on many of the splice variants that it has discovered, including all that are in its initial pipeline, and has already received patents on some. About Compugen Compugen, a genomics-based drug and diagnostic discovery company, increases the probability of successful development of novel drug and diagnostic products by incorporating ideas and methods from mathematics, computer science, and physics into the disciplines of biology, organic chemistry, and medicine. This unique capability results in powerful predictive models and discovery engines, which are both advancing the understanding of important biological phenomena and enabling the discovery of numerous potential therapeutic products and diagnostic markers. The Company has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the Company; additional discoveries have been out-licensed for development. Among Compugen's customers and partners are leading pharmaceutical and diagnostic companies, such as Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. , Diagnostic Products Corporation, Novartis, and Pfizer. For additional information, please visit Compugen's corporate Website at www.cgen.com. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements include words like "may," "expects," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the development of new products; the ability to implement technological improvements; the ability of Compugen to obtain and retain customers. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's annual reports filed on form 20F that are filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion